Results 171 to 180 of about 19,745 (243)

Chidamide, a Histone Deacetylase Inhibitor, Combined With R‐GemOx in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma (TRUST): A Multicenter, Single‐Arm, Phase 2 Trial

Cancer Medicine, Volume 14, Issue 9, May 2025.
ABSTRACT Background Histone deacetylase (HDAC) inhibitors demonstrated a synergistic anti‐tumor effect with rituximab and chemotherapy in preclinical studies on diffuse large B‐cell lymphoma (DLBCL). This phase 2 trial aimed to evaluate the efficacy and safety of chidamide, an orally active HDAC inhibitor, plus the R‐GemOx regimen for relapsed ...
Qihua Zou, Yuchen Zhang, Hui Zhou, Yulin Lai, Yi Cao, Zhiming Li, Ning Su, Wenyu Li, Huiqiang Huang, Panpan Liu, Xu Ye, Yudan Wu, Huo Tan, Runhui Zheng, Bingyi Wu, Hui Yang, Liye Zhong, Yuhong Lu, Yang Liang, Peng Sun, Lirong Li, Yingxian Liu, Danling Dai, Yi Xia, Qingqing Cai   +24 more
wiley   +1 more source

Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers. [PDF]

J Immunother Cancer
Kaur M, Rüger K, Chen EC, Rangaswamy US, Davison LM, Moreno Arteaga S, Smith I, Chu R, Chattopadhyay S, Rickert M, Force Aldred S, Harris KE, Trinklein ND, Clarke SC.   +13 more
europepmc   +1 more source

Alternative Immunosuppression in Acquired Haemophilia A

Haemophilia, EarlyView.
Jayna Mistry, Gillian Lowe, Will Lester, Charles Percy   +3 more
wiley   +1 more source

Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B‐Cell Lymphoma

Clinical Pharmacology &Therapeutics, Volume 117, Issue 5, Page 1437-1450, May 2025.
Epcoritamab is a CD3xCD20 bispecific antibody that activates T cells to kill CD20‐expressing B cells. Epcoritamab is approved for the treatment of adults with different types of relapsed or refractory lymphoma in various geographies, including the United States, Europe, and Japan.
Tommy Li, Leonid Gibiansky, Apurvasena Parikh, Matthew Putnins, Christopher W. Chiu, Mariana Sacchi, Huaibao Feng, Tahamtan Ahmadi, Manish Gupta, Steven Xu   +9 more
wiley   +1 more source

A novel <i>in vitro</i> serum stability assay for antibody therapeutics incorporating internal standards. [PDF]

MAbs
Li Y, Villafuerte-Vega R, Shenoy VM, Jackson HM, Wang Y, Parrish KE, Jenkins GJ, Sarvaiya H.   +7 more
europepmc   +1 more source

A cell-penetrating bispecific antibody suppresses hepatitis B virus replication and secretion. [PDF]

Virus Res
Xie C, Zhou B, Yao D, Wang X, Zhong L, Qiu C, Zhang J.   +6 more
europepmc   +1 more source

Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma

Clinical and Translational Science, Volume 18, Issue 5, May 2025.
ABSTRACT Mosunetuzumab, a CD20 × CD3 T‐cell‐engaging bispecific antibody, redirects T cells to eliminate malignant B cells. The purpose of YO43555 was to assess the pharmacokinetics (PK), safety, tolerability, and efficacy of mosunetuzumab as a single agent in Chinese patients with relapsed/refractory follicular lymphoma (R/R FL).
Junyi Li, Michael Z. Liao, Justin Wilkins, Elicia Penuel, Bei Wang, Shweta Vadhavkar, Kun Peng, Junning Cao, Zhiming Li, Ye Zhang, Wenjin Li, Donghang Li, Mingzhu Zhou, Michael C. Wei, Antonia Kwan, Rong Zhao, Chunze Li, Chi‐Chung Li, David C. Turner   +18 more
wiley   +1 more source

A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy. [PDF]

Antibodies (Basel)
Justiz-Vaillant A, Pandit BR, Unakal C, Vuma S, Akpaka PE.   +4 more
europepmc   +1 more source

Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives

European Journal of Haematology, Volume 114, Issue 5, Page 775-784, May 2025.
ABSTRACT Follicular lymphoma (FL) is a prevalent indolent non‐Hodgkin lymphoma (NHL) characterized by a relapsing course and eventual refractoriness to therapy. Despite advancements in treatment, FL remains incurable, necessitating ongoing research into novel therapeutic strategies.
Giulio Caridà, Enrica Antonia Martino, Antonella Bruzzese, Daniele Caracciolo, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Teresa Rossi, Antonino Neri, Ernesto Vigna, Pierfrancesco Tassone, Pierosandro Tagliaferri, Fortunato Morabito, Massimo Gentile   +14 more
wiley   +1 more source

Evaluation of an anti-CD3 VHH and construction of an anti-CD3/anti-EGFR bispecific tandem VHH as a cancer cell targeting drug construct. [PDF]

Biochem Biophys Rep
Asanuma T, Ding P, Kato Y, Nakanishi T, Asano R, Makabe K.   +5 more
europepmc   +1 more source